We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review.
- Authors
Pinnix, Chelsea C.; Shah, Jatin J.; Chuang, Hubert; Costelloe, Colleen M.; Medeiros, L. Jeffrey; Wogan, Christine F.; Reed, Valerie; Smith, Grace L.; Milgrom, Sarah; Patel, Krina; Huo, Jinhai; Turturro, Francesco; Romaguera, Jorge; Fayad, Luis; Oki, Yasuhiro; Fanale, Michelle A.; Westin, Jason; Nastoupil, Loretta; Hagemeister, Fredrick B.; Rodriguez, Alma
- Abstract
<bold>Background: </bold>Plasmablastic lymphoma (PBL) is an aggressive variant of diffuse large B-cell lymphoma. We sought to assess the treatment outcomes after combined-modality therapy for early-stage PBL.<bold>Materials and Methods: </bold>We retrospectively reviewed the outcomes of 10 consecutive patients diagnosed with stage I-II PBL from February 2001 to December 2013 at a single institution. The baseline clinical characteristics, treatment modalities, overall outcomes, and treatment-related toxicity were assessed.<bold>Results: </bold>The median age at diagnosis was 50.5 years. All patients had extranodal disease; 2 were positive for human immunodeficiency virus. Seven patients received hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone)-based chemotherapy, 2 received CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), and 1 received dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin). Radiotherapy (RT) was administered after a complete response to chemotherapy in 7 patients and a partial response in 1 patient. At a median follow-up period of 42 months, the estimated 2-year progression-free and overall survival rates were 90% and 100%, respectively.<bold>Conclusion: </bold>PBL can be successfully treated with aggressive chemotherapy followed by RT. The treatment was well tolerated and can result in long-term survival for patients with limited-stage disease.
- Publication
Clinical Lymphoma, Myeloma & Leukemia, 2016, Vol 16, Issue 3, p122
- ISSN
2152-2650
- Publication type
journal article
- DOI
10.1016/j.clml.2015.12.008